Evaluation of treatment patterns and survival among patients with diffuse large B-cell lymphoma in the USA

24Citations
Citations of this article
47Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Aim: To evaluate treatment patterns of diffuse large B-cell lymphoma (DLBCL). Patients & methods: First-line and relapsed/refractory treatment patterns and survival outcomes following first-line therapy in adult patients newly diagnosed with DLBCL were evaluated. Results: A total of 1436 DLBCL patients initiated treatment and mainly received a combination regimen versus monotherapy (92.1 vs 7.9%). Patients who received monotherapy were older with more comorbidities and had shorter progression-free survival than patients receiving combination therapy (median: 31.3 vs 55.8 months). In the second-line setting (n = 164), rituximab-based combination regimens were most common; 25% underwent stem cell transplantation, and were younger with fewer comorbidities. Conclusion: These results illustrate the need for new treatment options for patients unable to tolerate initial combination therapy and transplant-ineligible patients who require salvage therapy.

Cite

CITATION STYLE

APA

Morrison, V. A., Shou, Y., Bell, J. A., Hamilton, L., Ogbonnaya, A., Raju, A., … Galaznik, A. (2019). Evaluation of treatment patterns and survival among patients with diffuse large B-cell lymphoma in the USA. Future Oncology, 15(9), 1021–1034. https://doi.org/10.2217/fon-2018-0788

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free